Should ustekinumab really be used as first-line biological therapy in pityriasis rubra pilaris?

British Journal of Dermatology

Volumn 163, Issue 4, 2010, Pages 896-897

  Balestri, R ^a   Bardazzi, F ^a   Antonucci, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

pityriasis rubra pilaris; tumour necrosis factor ; ustekinumab

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA ANTIBODY; USTEKINUMAB;

DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; PITYRIASIS RUBRA PILARIS; PRIORITY JOURNAL; PSORIASIS VULGARIS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OFF-LABEL USE; PITYRIASIS RUBRA PILARIS;

EID: 77957040954     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09942.x     Document Type: Letter

References (5)

1. Wohlrab J, Kreft B. Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol 2010 163 : 655 656.
2. Garcovich S, Di Giampetruzzi AR, Antonelli G et al. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereo 2010 24 : 881 884.
3. Elliott M, Benson J, Blank M et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci 2009 1182 : 97 110.
4. [No authors listed]. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients. Prescrire Int 2009 18 : 202 204.
5. Müller H, Gattringer C, Zelger B et al. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. J Am Acad Dermatol 2008 59 : S65 70.